Frauke Christ

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2193657/publications.pdf

Version: 2024-02-01

49 papers	2,085 citations	331259 21 h-index	233125 45 g-index
54 all docs	54 docs citations	54 times ranked	2033 citing authors

#	Article	IF	Citations
1	Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nature Chemical Biology, 2010, 6, 442-448.	3.9	428
2	Transportin-SR2 Imports HIV into the Nucleus. Current Biology, 2008, 18, 1192-1202.	1.8	231
3	The Interaction of LEDGF/p75 with Integrase Is Lentivirus-specific and Promotes DNA Binding. Journal of Biological Chemistry, 2005, 280, 17841-17847.	1.6	182
4	Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization. Antimicrobial Agents and Chemotherapy, 2012, 56, 4365-4374.	1.4	158
5	The LEDGF/p75 integrase interaction, a novel target for anti-HIV therapy. Virology, 2013, 435, 102-109.	1.1	96
6	LEDGIN-mediated Inhibition of Integraseâ€“LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV. EBioMedicine, 2016, 8, 248-264.	2.7	90
7	Host factors for retroviral integration site selection. Trends in Biochemical Sciences, 2015, 40, 108-116.	3.7	83
8	Multiple cellular proteins interact with LEDGF/p75 through a conserved unstructured consensus motif. Nature Communications, 2015, 6, 7968.	5.8	53
9	Interaction of the HIV-1 Intasome with Transportin 3 Protein (TNPO3 or TRN-SR2). Journal of Biological Chemistry, 2012, 287, 34044-34058.	1.6	52
10	4-Substituted 2-Hydroxyisoquinoline-1,3(2H,4H)-diones as a Novel Class of HIV-1 Integrase Inhibitors. ACS Medicinal Chemistry Letters, 2013, 4, 606-611.	1.3	52
11	Interplay between HIV Entry and Transportin-SR2 Dependency. Retrovirology, 2011, 8, 7.	0.9	51
12	Lentiviral nuclear import: a complex interplay between virus and host. BioEssays, 2007, 29, 441-451.	1.2	42
13	Kuwanonâ€Ł as a New Allosteric HIVâ€ł Integrase Inhibitor: Molecular Modeling and Biological Evaluation. ChemBioChem, 2015, 16, 2507-2512.	1.3	39
14	Capsid-Labelled HIV To Investigate the Role of Capsid during Nuclear Import and Integration. Journal of Virology, 2020, 94, .	1.5	34
15	LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis. Blood, 2018, 131, blood-2017-05-786962.	0.6	32
16	Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach. Frontiers in Chemistry, 2019, 7, 574.	1.8	32
17	The HIV-1 Integrase Mutant R263A/K264A Is 2-fold Defective for TRN-SR2 Binding and Viral Nuclear Import. Journal of Biological Chemistry, 2014, 289, 25351-25361.	1.6	28
18	Dynamic Oligomerization of Integrase Orchestrates HIV Nuclear Entry. Scientific Reports, 2016, 6, 36485.	1.6	28

#	Article	IF	Citations
19	Affinity switching of the LEDGF/p75 IBD interactome is governed by kinase-dependent phosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7053-E7062.	3.3	27
20	Insight in HIV Integration Site Selection Provides a Block-and-Lock Strategy for a Functional Cure of HIV Infection. Viruses, 2019, 11, 12.	1.5	26
21	Phenotyping of Rare CFTR Mutations Reveals Distinct Trafficking and Functional Defects. Cells, 2020, 9, 754.	1.8	23
22	The mutation of Transportin 3 gene that causes limb girdle muscular dystrophy 1F induces protection against HIV-1 infection. PLoS Pathogens, 2019, 15, e1007958.	2.1	22
23	Impact of LEDGIN treatment during virus production on residual HIV-1 transcription. Retrovirology, 2019, 16, 8.	0.9	22
24	Synthesis, Molecular Modelling and Biological Studies of 3-hydroxypyrane- 4-one and 3-hydroxy-pyridine-4-one Derivatives as HIV-1 Integrase Inhibitors. Medicinal Chemistry, 2019, 15, 755-770.	0.7	22
25	Proteinâ€“protein and proteinâ€“chromatin interactions of LEDGF/p75 as novel drug targets. Drug Discovery Today: Technologies, 2017, 24, 25-31.	4.0	21
26	Diketoacid chelating ligands as dual inhibitors of HIV-1 integration process. European Journal of Medicinal Chemistry, 2014, 78, 425-430.	2.6	17
27	A new potential approach to block HIV-1 replication via proteinâ€“protein interaction and strand-transfer inhibition. Bioorganic and Medicinal Chemistry, 2014, 22, 2269-2279.	1.4	17
28	GS-9822, a Preclinical LEDGIN Candidate, Displays a Block-and-Lock Phenotype in Cell Culture. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	17
29	Design and discovery of 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide inhibitors of HIV-1 integrase. Bioorganic and Medicinal Chemistry, 2014, 22, 5446-5453.	1.4	15
30	Inhibitors of the integraseâ€“transportin-SR2 interaction block HIV nuclear import. Retrovirology, 2018, 15, 5.	0.9	14
31	De novo design of small molecule inhibitors targeting the LEDGF/p75-HIVintegrase interaction. RSC Advances, 2012, 2, 974-984.	1.7	13
32	Structure of transportin SR2, a karyopherin involved in human disease, in complex with Ran. Acta Crystallographica Section F, Structural Biology Communications, 2014, 70, 723-729.	0.4	11
33	2-hydroxyisoquinoline-1,3(2 H ,4 H)-diones (HIDs) as human immunodeficiency virus type 1 integrase inhibitors: Influence of the alkylcarboxamide substitution of position 4. European Journal of Medicinal Chemistry, 2016, 117, 256-268.	2.6	11
34	N-terminal half of transportin SR2 interacts with HIV integrase. Journal of Biological Chemistry, 2017, 292, 9699-9710.	1.6	11
35	Synthesis of new pyridazine derivatives as potential antiâ€HIVâ€1 agents. Journal of Heterocyclic Chemistry, 2009, 46, 1420-1424.	1.4	9
36	HIV-1 integrase inhibition: looking at cofactor interactions. Future Medicinal Chemistry, 2015, 7, 2407-2410.	1.1	9

#	Article	IF	Citations
37	Towards a Functional Cure of HIV-1: Insight Into the Chromatin Landscape of the Provirus. Frontiers in Microbiology, 2021, 12, 636642.	1.5	9
38	Lessons Learned: HIV Points the Way Towards Precision Treatment of Mixed-Lineage Leukemia. Trends in Pharmacological Sciences, 2016, 37, 660-671.	4.0	8
39	LEDGF/p75-mediated chemoresistance of mixed-lineage leukemia involves cell survival pathways and super enhancer activators. Cancer Gene Therapy, 2022, 29, 133-140.	2.2	7
40	LEDGINs, Inhibitors of the Interaction Between HIV-1 Integrase and LEDGF/p75, Are Potent Antivirals with a Potential to Cure HIV Infection. Advances in Experimental Medicine and Biology, 2021, 1322, 97-114.	0.8	6
41	Role of Transportin-SR2 in HIV-1 Nuclear Import. Viruses, 2021, 13, 829.	1.5	6
42	Unlike its Paralog LEDGF/p75, HRP-2 Is Dispensable for MLL-R Leukemogenesis but Important for Leukemic Cell Survival. Cells, 2021, 10, 192.	1.8	5
43	Validation of host factors of HIV integration as novel drug targets for anti-HIV therapy. MedChemComm, 2014, 5, 314-320.	3.5	4
44	Optimization of rhodanine scaffold for the development of proteinâ€“protein interaction inhibitors. Bioorganic and Medicinal Chemistry, 2015, 23, 3208-3214.	1.4	4
45	Molecular Mechanism of LEDGF/p75 Dimerization. Structure, 2020, 28, 1288-1299.e7.	1.6	4
46	LEDGF/p75 and transportin-SR2 are cellular cofactors of HIV integrase and novel targets for antiviral therapy. HIV Therapy, 2009, 3, 171-188.	0.6	4
47	CRISPR/Cas9-Induced Mutagenesis Corroborates the Role of Transportin-SR2 in HIV-1 Nuclear Import. Microbiology Spectrum, 2021, 9, e0133621.	1.2	3
48	Insight into HIV-2 latency may disclose strategies for a cure for HIV-1 infection. Journal of Virus Eradication, 2017, 3, 7-14.	0.3	3
49	Design, synthesis, in silico studies, and antiproliferative evaluations of novel indolin-2-one derivatives containing 3-hydroxy-4-pyridinone fragment. Bioorganic and Medicinal Chemistry Letters, 2022, 70, 128784.	1.0	3